Harvard Bioscience
HBIO
Harvard Bioscience (HBIO) analyst forecast and price target
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Benchmark | Maintained | Speculative Buy | $7.50 from $6.00 | Aug 12, 2026 |
| Benchmark | Maintained | Speculative Buy | $6.00 from $0.60 | Mar 16, 2026 |
| Benchmark | Maintained | Speculative Buy | $0.60 from $2.00 | Mar 13, 2026 |
| Benchmark | Maintained | Speculative Buy | $2.00 from $3.00 | Sep 10, 2025 |
| Benchmark | Maintained | Speculative Buy | $3.00 from $4.50 | May 13, 2025 |
| Keybanc | Downgraded | Overweight → Sector Weight | — | Apr 9, 2025 |
| Keybanc | Downgraded | Overweight → Sector Weight | — | Apr 8, 2025 |
| Benchmark | Maintained | Speculative Buy | $4.50 from $5.50 | Mar 24, 2025 |
| Benchmark | Maintained | Speculative Buy | $7.00 | Jun 22, 2023 |
| Benchmark | Maintained | Buy | $7.00 from $4.00 | Apr 26, 2023 |
| Keybanc | Maintained | Overweight | $7.00 from $5.00 | Apr 26, 2023 |
| Benchmark | Maintained | Buy | $4.00 | Mar 10, 2023 |
Frequently asked questions
What is the latest analyst rating on HBIO?
On Aug 12, 2026, Benchmark maintained Harvard Bioscience at Speculative Buy with a price target of $7.50.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.